Nonspecified Long-chain Fatty Acid Synthetase: Potential Drug Target Or Biomarker

Target Name: Long-chain-fatty-acid--CoA ligase

NCBI ID: P11349

Long-chain-fatty-acid--CoA ligase

Nonspecified Long-chain Fatty Acid Synthetase: Potential Drug Target Or Biomarker

Long-chain-fatty-acid--CoA ligase (nonspecified subtype) (Long-chain acyl-CoA synthetase), also known as 2-acyl-CoA synthetase, is an enzyme involved in the synthesis of long-chain fatty acids from tryptophan or other amino acids. This enzyme catalyzes the conversion of CoA to long-chain fatty acids, which are important substrates for various cellular processes, including energy metabolism and the synthesis of lipids. Long-chain fatty acids have a series of benefits, including a higher energy density and a reduced risk of certain diseases, such as heart disease and diabetes.

The nonspecified subtype of long-chain acyl-CoA synthetase, also known as 2-acyl-CoA synthetase, is a critical enzyme in the synthesis of long-chain fatty acids. This enzyme catalyzes the conversion of CoA to long-chain fatty acids, which are important substrates for various cellular processes, including energy metabolism and the synthesis of lipids. The nonspecified subtype of long-chain acyl-CoA synthetase is an enzyme that is expressed in various tissues and cells throughout the body, including the liver, muscle, and heart.

One of the key benefits of the nonspecified subtype of long-chain acyl-CoA synthetase is its role in the synthesis of long-chain fatty acids. Long-chain fatty acids have a higher energy density than short-chain fatty acids, which means they can provide more energy per gram of weight. Additionally, long-chain fatty acids are resistant to oxidation and can help to reduce the risk of certain diseases, such as heart disease and diabetes. The nonspecified subtype of long-chain acyl-CoA synthetase is also involved in the synthesis of other molecules, including lipids, which are important for maintaining cellular health and function.

The nonspecified subtype of long-chain acyl-CoA synthetase is also a potential drug target or biomarker. The nonspecified subtype of long-chain acyl-CoA synthetase has been shown to play a role in the development and progression of certain diseases, including heart disease and diabetes. Additionally, the nonspecified subtype of long-chain acyl-CoA synthetase has been shown to be involved in the regulation of cellular processes, including cell growth and metabolism.

In conclusion, the nonspecified subtype of long-chain acyl-CoA synthetase is an important enzyme involved in the synthesis of long-chain fatty acids. This enzyme has been shown to play a role in the development and progression of certain diseases, including heart disease and diabetes. Additionally, the nonspecified subtype of long-chain acyl-CoA synthetase has been shown to be involved in the regulation of cellular processes, including cell growth and metabolism. As a result, the nonspecified subtype of long-chain acyl-CoA synthetase may be a potential drug target or biomarker for the treatment of certain diseases. Further research is needed to fully understand the role of the nonspecified subtype of long-chain acyl-CoA synthetase in cellular processes and its potential as a drug target or biomarker.

Protein Name: Long-chain-fatty-acid--CoA Ligase (nonspecified Subtype)

The "Long-chain-fatty-acid--CoA ligase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Long-chain-fatty-acid--CoA ligase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets